Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study

被引：373

作者：

Kudoh, Shoji ^{[2
]}

Kato, Harubumi ^{[4
]}

Nishiwaki, Yutaka ^{[3
]}

Fukuoka, Masahiro ^{[5
]}

Nakata, Kouichiro ^{[6
]}

Ichinose, Yukito ^{[7
]}

Tsuboi, Masahiro ^{[4
]}

Yokota, Soichiro ^{[8
]}

Nakagawa, Kazuhiko ^{[5
]}

Suga, Moritaka ^{[9
]}

Jiang, Haiyi ^{[11
]}

Itoh, Yohji ^{[11
]}

Armour, Alison ^{[12
]}

Watkins, Claire ^{[12
]}

Higenbottam, Tim ^{[13
,14
]}

Nyberg, Fredrik ^{[1
,15
]}

机构：

[1] AstraZeneca R&D, Epidemiol, SE-41383 Molndal, Sweden

[2] Nippon Med Sch, Tokyo 113, Japan

[3] Natl Canc Ctr Hosp E, Chiba, Japan

[4] Tokyo Med Univ Hosp, Tokyo, Japan

[5] Kinki Univ, Sch Med, Osaka 589, Japan

[6] Nakata Clin, Tokyo, Japan

[7] Kyushu Natl Canc Ctr, Fukuoka, Japan

[8] Toneyama Natl Hosp, Osaka, Japan

[9] Saiseikai Kumamoto Hosp, Kumamoto, Japan

[10] Japan Thorac Radiol Grp, Shiga, Japan

[11] AstraZeneca KK, Osaka, Japan

[12] AstraZeneca, Macclesfield, Cheshire, England

[13] Univ Sheffield, Sheffield, S Yorkshire, England

[14] AstraZeneca R&D Charnwood, Loughborough, Leics, England

[15] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2008年 / 177卷 / 12期

关键词：

non-small cell lung cancer; interstitial lung disease; Japanese patients; gefitinib; chemotherapy;

D O I：

10.1164/rccm.200710-1501OC

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Rationale: Interstitial lung disease (ILD) occurs in Japanese patients with non-small cell lung cancer (NSCLC) receiving gefitinib. Objectives: To elucidate risk factors for ILD in Japanese patients with NSCLC during treatment with gefitinib or chemotherapy. Methods: In a prospective epidemiologic cohort, 3,166 Japanese patients with advanced/recurrent NSCLC were followed for 12 weeks on 250 mg gefitinib (n = 1,872 treatment periods) or chemotherapy (n = 2,551). Patients who developed acute ILD (n = 122) and randomly selected control subjects (n = 574) entered a case-control study. Adjusted incidence rate ratios were estimated from case-control data by odds ratios (ORs) with 95% confidence intervals (CIs) using logistic regression. Crude (observed) incidence rates and risks were calculated from cohort data. Measurements and Main Results: The observed (unadjusted) incidence rate over 12 weeks was 2.8 (95% CI, 2.3-3.3) per 1,000 person-weeks, 4.5 (3.5-5.4) for gefitinib versus 1.7 (1.2-2.2) for chemotherapy; the corresponding observed naive cumulative incidence rates at the end of 12-week follow-up were 4.0% (3.0-5.1%) and 2.1% (1.5-2.9%), respectively. Adjusted for imbalances in risk factors between treatments, the overall OR for gefitinib versus chemotherapy was 3.2 (1.9-5.4), elevated chiefly during the first 4 weeks (3.8 [1.9-7.7]). Other ILD risk factors in both groups included the following: older age, poor World Health Organization performance status, smoking, recent NSCLC diagnosis, reduced normal lung on computed tomography scan, preexisting chronic ILD, concurrent cardiac disease. ILD-related deaths in patients with ILD were 31.6% (gefitinib) versus 27.9% (chemotherapy); adjusted OR, 1.05 (95% CI, 0.3-3.2). Conclusions: ILD was relatively common in these Japanese patients with NSCLC during therapy with gefitinib or chemotherapy, being higher in the older, smoking patient with preexisting ILD or poor performance status. The risk of developing ILD was higher with gefitinib than chemotherapy, mainly in the first 4 weeks.

引用

页码：1348 / 1357

页数：10

共 30 条

[1] Radiation-induced and chemotherapy-induced pulmonary injury [J].

Abid, SH ;

Malhotra, V ;

Perry, MC .

CURRENT OPINION IN ONCOLOGY, 2001, 13 (04) :242-248

[2]

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, Am J Respir Crit Care Med, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]

[3] Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib [J].